The association of serum-free light-chain levels with markers of renal function

Figures & data

Table 1. Patient demographic and biochemical data.

	Median (min–max)
	Group 1 (GFR ≤ 60, n = 103)	Group 2 (GFR > 60, n = 410)
Age (years)	69 (40–85)	60 (19–83)
Creatinine (mg/dL)	1.56 (0.63–7.21)	0.77 (0.29–1.74)
eGFR (mL/min)	40 (8–60)	93 (61–135)
Free kappa (mg/L)	36.4 (5.62–16,000)	20.8 (5.34–16,000)
Free lambda (mg/L)	21.7 (4.91–8770)	16.4 (4.91–1700)
κ/λ ratio	1.33 (0.01–516.02)	1.24 (0.01–2851.41)

Table 2. Spearman correlation coefficients for λ sFLC, κ/λ ratio, creatinine and eGFR in Group 1 patients.

	Creatinine	eGFR (mL/min)
λ sFLC	0.260**	−0.318**
κ/λ ratio	−0.263**	0.198*

Notes: Correlations are significant at the *0.05 level and **0.001 level.

Figure 1. Serum kappa-free light-chain concentrations in Group 1 patients. Kappa sFLC increased dramatically in CKD stages (p < 0.05).

Figure 2. Serum lambda-free light-chain concentrations in Group 1 patients. Serum-free lambda light chains increased progressively with each CKD stage (p < 0.05).

Figure 3. Serum-free kappa/lambda ratio in Group 1 patients. Serum-free kappa/lambda ratio decreased dramatically in CKD stage 5 (p < 0.05).